Navigation Links
Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
Date:5/16/2008

MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. In addition, the Company has nominated MEM 68626 as the lead development candidate from its 5-HT6 antagonist program, and separately confirmed its 2008 development goals for its pipeline.

"We are extremely excited about the progress we have made in advancing our programs," said Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "MEM 1414 produced a robust CNS signal in a human quantitative EEG study. In addition, using human whole blood assays, we have identified plasma concentrations required for anti-inflammatory activity. These data, combined with previous pharmacokinetic and safety data obtained in Phase 1 clinical trials for MEM 1414, will guide dosing for a proof-of-concept trial in either a cognition or respiratory indication, which we expect to initiate by the end of 2008."

Mr. Kailian continued, "Further, we are pleased to report that we have nominated MEM 68626 as the lead compound in our 5-HT6 antagonist program. MEM 68626 has demonstrated strong preclinical efficacy data in cognition and has a favorable safety and pharmacokinetic profile, which we believe offers advantages over other compounds in development. We look forward to advancing MEM 68626 into the clinic this year."

MEM 1414 - Potential in Cognition and Inflammation

Memory Pharmaceuticals reported the results of a clinical study of MEM 1414 on quantitative EEG (qEEG), a bio
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. How Big Is Your Brain? Its Size May Protect You from Memory Loss
8. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... , Sept. 1, 2014 Reportbuyer.com ... Rigid Transparent Plastics: Global Markets ... INTRODUCTION This chapter ... describing the study goals and objectives, reasons ... methodology, information sources and analyst credentials, and ...
(Date:8/30/2014)... 30, 2014   Royal Philips  (NYSE: PHG, AEX: ... a new ultrasound system designed to enable global hospitals ... patient volumes and cost pressures. Making its debut at ... Barcelona this week, Affiniti provides ... with fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Rigid Transparent Plastics: Global Markets Outside North America 2Rigid Transparent Plastics: Global Markets Outside North America 3Rigid Transparent Plastics: Global Markets Outside North America 4Rigid Transparent Plastics: Global Markets Outside North America 5Rigid Transparent Plastics: Global Markets Outside North America 6Rigid Transparent Plastics: Global Markets Outside North America 7Rigid Transparent Plastics: Global Markets Outside North America 8Rigid Transparent Plastics: Global Markets Outside North America 9Rigid Transparent Plastics: Global Markets Outside North America 10Rigid Transparent Plastics: Global Markets Outside North America 11Rigid Transparent Plastics: Global Markets Outside North America 12Rigid Transparent Plastics: Global Markets Outside North America 13Rigid Transparent Plastics: Global Markets Outside North America 14Rigid Transparent Plastics: Global Markets Outside North America 15Rigid Transparent Plastics: Global Markets Outside North America 16Rigid Transparent Plastics: Global Markets Outside North America 17Rigid Transparent Plastics: Global Markets Outside North America 18Rigid Transparent Plastics: Global Markets Outside North America 19Rigid Transparent Plastics: Global Markets Outside North America 20Rigid Transparent Plastics: Global Markets Outside North America 21Rigid Transparent Plastics: Global Markets Outside North America 22Rigid Transparent Plastics: Global Markets Outside North America 23Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4Implementing a Strategic Thought Leader Management & Engagement System 2
... of GDIR Agonists Under its ... Partnership ... Inc.,(Nasdaq: ARNA ) announced today that initial clinical study ... being investigated,for the treatment of type 2 diabetes under a ...
... following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) ... tolerability comparable to placebo ... Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., Jan. ... a 4-week Phase 1,clinical trial to evaluate two oral dose levels of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6
(Date:9/2/2014)... Falls, New York (PRWEB) September 02, 2014 ... ?” This is the question that millions of people ... among health care providers, patients and their families or ... to misdiagnosis due to its distinct similarities to other ... dermatitis, impetigo, bed bug bites, eczema, varicella and many ...
(Date:9/2/2014)... September 02, 2014 Michigan’s health care ... Care Act and the Healthy Michigan Plan. Throughout these ... remains a trusted funding resource for under-served individuals. Federal ... uninsured or underinsured women between the ages of 50 ... 250 percent of the federal poverty level. ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides ... collection of employee internet monitoring products ( http://www.os-monitor.com ). ... up to 10% off, on these useful items. ... than 20 different kinds of high end monitoring programs ... for companies of all sizes. With its high end ...
(Date:9/2/2014)... Barcelona, Spain Tuesday 2 September 2014: A simple ... atrial fibrillation (AF), according to research presented at ESC ... Professor Davy said: "Atrial fibrillation (AF) is the most ... failure risk by three-fold and the risk of stroke ... stroke in 1 of 4 cases. However, AF is ...
(Date:9/2/2014)... California (PRWEB) September 02, 2014 Developers ... have announced a new ProIntro Lesson from Pixel Film ... create easy and fresh-looking titles,” said Christina Austin, CEO ... and armature, ProIntro is a definite game changer.” , ... the ProIntro Lesson from Pixel Film Studios. ProIntro is ...
Breaking Medicine News(10 mins):Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3
... been sent to people traveling to the Indian Ocean. ... bites.// ,93 cases have been reported by ... last year’s average of 6. ,According to the HPA's ... had cases of mosquito-borne virus.,Insect repellents, long trousers and ...
... of the awareness of obesity epidemic afflicting the kids in ... of these actions is not up to the mark. ... Progress in Preventing Childhood Obesity: How Do We Measure Up?, ... ,"The very health of the country hangs in ...
... “crisis” over lack of donors at sperm bank clinics. According to ... stock//, women and couples wanting to have children were facing a ... was 459. Ever since, the number had been decreasing. To make ... kids the right to know the identity of their donor father ...
... start by next week the distribution of a drug to ... ,South Africa is being affected by an extremely virulent ... 52 people in the country. The health officials have now ... early as next week to help fight the disease. The ...
... US is asking for an extensive study for the evaluation ... the use of stents. // ,Stents are widely ... eluting stents are had essentially eliminated short-term restenosis as a ... come under a cloud for possible late-term risks. Reports indicate ...
... In a unique way to curb binge drinking, researchers say parents ... that allowing youngsters // to drink at parties and at home ... ,Professor Mark Bellis, the author of the report said ... in moderation and allowed to drink with them were sensible in ...
Cached Medicine News:Health News:Slow Fight Against Childhood Obesity 2Health News:Slow Fight Against Childhood Obesity 3Health News:Shortage of donors at sperm bank clinics 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: